Benitec Biopharma Inc.
For the period ended Jun 30, 2025. Filed Sep 22, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Sep 22, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized, in the city of Hayward, State of California, on the 22nd day of September 2025.
| BENITEC BIOPHARMA INC. | |
|---|---|
| By: | /s/ Dr. Jerel Banks |
| Dr. Jerel Banks | |
| Chief Executive Officer | |
POWER OF ATTORNEY
BY THESE PRESENTS, each person whose signature appears below constitutes and appoints Dr. Jerel Banks and Megan Boston his true and lawful attorney-in-fact and agents, with full power of substitution and resubstitution for him and in his name, place and stead, in any and all capacities to sign any and all amendments to this annual report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the U.S. Securities and Exchange Commission, hereby ratifying and confirming all that said attorney-in-fact or his substitute, each acting alone, may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Dr. Jerel Banks Dr. Jerel Banks | Chief Executive Officer, Chairman of the Board and Director (principal executive officer) | September 22, 2025 |
| /s/ Megan Boston Megan Boston | Chief Financial Officer, Director (principal accounting and financialofficer) | September 22, 2025 |
| /s/ J. Kevin Buchi J. Kevin Buchi | Director | September 22, 2025 |
| /s/ Peter Francis Peter Francis | Director | September 22, 2025 |
| /s/ Edward Smith Edward Smith | Director | September 22, 2025 |
| /s/ Kishan (“Kishen”) Mehta Kishan (“Kishen”) Mehta | Director | September 22, 2025 |
IV-5
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.